3 October 2024 - Today, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb) with platinum-doublet chemotherapy as neo-adjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

Efficacy was evaluated in CHECKMATE-77T, a randomised, double-blind, placebo-controlled multi-centre trial in 461 patients with previously untreated and resectable non-small cell lung cancer (stage IIA to select stage IIIB [AJCC, 8th edition]).

Read FDA News